We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$104M
AUM Growth
-$15.6M
Cap. Flow
+$5.76M
Cap. Flow %
5.56%
Top 10 Hldgs %
71.2%
Holding
45
New
12
Increased
6
Reduced
6
Closed
13

Top Buys

Rank Stock Value
1
TWM icon
ProShares UltraShort Russell2000
TWM
+$9.12M
2
AGN
Allergan plc
AGN
+$6.71M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.53M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$2.66M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.04M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$4.86M
2
MRK icon
Merck
MRK
+$4.53M
3
SNY icon
Sanofi
SNY
+$3.07M
4
AZN icon
AstraZeneca
AZN
+$1.83M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$1.59M

Sector Composition

Rank Sector Weight
1 Healthcare 53.84%
2 Miscellaneous 46.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TWM icon
1
ProShares UltraShort Russell2000
TWM
$44M
$11.1M 10.69%
11,250
+10,000
+800% +$9.12M
AMRI
2
DELISTED
Albany Molecular Research Inc
AMRI
$11M 10.61%
498,200
– –
ANIP icon
3
ANI Pharmaceuticals
ANIP
$1.69B
$9.9M 9.55%
350,000
+151,000
+76% +$4.53M
AGN
4
DELISTED
Allergan plc
AGN
$7.24M 6.98%
+30,000
New +$6.71M
AGN
5
CALL
DELISTED
Allergan plc
AGN
$6.03M 5.82%
+25,000
New +$5.59M
AUXL
6
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$5.97M 5.76%
200,000
+100,000
+100% +$2.12M
MRK icon
7
CALL
Merck
MRK
$369B
$5.93M 5.72%
+104,800
New +$5.88M
PFE icon
8
CALL
Pfizer
PFE
$160B
$5.91M 5.71%
+210,800
New +$5.92M
TEVA icon
9
Teva Pharmaceuticals
TEVA
$43.8B
$5.38M 5.19%
100,000
-30,000
-23% -$1.59M
AZN icon
10
AstraZeneca
AZN
$255B
$5.36M 5.17%
75,000
-25,000
-25% -$1.83M
DGX icon
11
Quest Diagnostics
DGX
$27B
$4.68M 4.52%
77,208
– –
AZN icon
12
CALL
AstraZeneca
AZN
$255B
$3.57M 3.45%
+50,000
New +$3.66M
VXX
13
CALL
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
$3.12M 3.01%
+6,250
New +$2.89M
PFE icon
14
Pfizer
PFE
$160B
$2.96M 2.85%
105,400
-52,700
-33% -$1.48M
BMY icon
15
PUT
Bristol-Myers Squibb
BMY
$137B
$2.56M 2.47%
+50,000
New +$2.5M
BIS icon
16
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$2.41M 2.32%
5,000
– –
LGND icon
17
Ligand Pharmaceuticals
LGND
$5.67B
$2.35M 2.27%
+80,150
New +$2.66M
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
$1.13M 1.09%
+25,000
New +$1.04M
SRNE
19
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.09M 1.05%
240,968
+36,000
+18% +$193K
RIGL icon
20
Rigel Pharmaceuticals
RIGL
$875M
$776K 0.75%
40,000
+30,000
+300% +$847K
AORT icon
21
Artivion
AORT
$1.3B
$740K 0.71%
+75,000
New +$737K
VIRX
22
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$714K 0.69%
476
-238
-33% -$345K
CEMP
23
DELISTED
Cempra, Inc.
CEMP
$548K 0.53%
50,000
– –
ARIA
24
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$540K 0.52%
+100,000
New +$584K
ARIA
25
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$540K 0.52%
100,000
+25,000
+33% +$146K
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q3 2014 Portfolio in Review

As of Q3 2014, Healthcare Value Capital held 45 positions worth $104M, down 13% from $119M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Healthcare Value Capital deployed $5.76M of net new capital in Q3 2014, opening 12 new positions and adding to 6 existing holdings. Its largest new stake was Allergan plc: 30,000 shares worth $7.24M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 47% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AstraZeneca, an estimated $1.83M trimmed.

  • Healthcare Value Capital's largest Q3 2014 buy was Allergan plc: 30,000 shares worth $7.24M.
  • Healthcare Value Capital added most to ProShares UltraShort Russell2000 in Q3 2014, an estimated $9.12M increase.
  • Healthcare Value Capital's biggest Q3 2014 reduction was AstraZeneca, cutting an estimated $1.83M.
  • Healthcare Value Capital fully exited AUXILIUM PHARAMCEUTICALS INC in Q3 2014, selling an estimated $4.86M.
  • Healthcare Value Capital's ten largest holdings make up 71% of its $104M portfolio in Q3 2014.
  • Healthcare Value Capital opened 12 new positions and closed 13 in Q3 2014.
  • Healthcare Value Capital's portfolio value fell 13% quarter-over-quarter to $104M.

Based on Healthcare Value Capital's 13F filing for Q3 2014, filed 13 Nov 2014.